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ABSTRACT
Results from the OPPERA study provided evidence that risk factors such as neck muscle tension,
prolonged jaw opening, and female gender increase the likelihood of developing
temporomandibular joint disorders (TMJD), which are prevalent, debilitating orofacial pain
conditions. Peripheral and central sensitization, which mediate a lowering of the stimulus
required for pain signaling, are implicated in the underlying pathology of chronic TMJD. The
goal of my study was to investigate cellular changes in the expression of proteins associated with
the development of central sensitization. Female Sprague-Dawley rats were injected with
complete Freund’s adjuvant in the upper trapezius muscles to promote trigeminal sensitization.
After 8 days, animals were subjected to near maximal jaw opening for 20 minutes, and spinal
cord tissues were collected at several time points until day 28 post jaw opening. Changes in
proteins associated with neuronal and glial cell activation were investigated in the medullary
dorsal horn using immunohistochemistry. Somewhat surprisingly, consistently increased protein
expression was not observed in second-order nociceptive neurons, astrocytes, or microglia in the
dorsal horn. Thus, my results are suggestive that this novel model for inducing chronic TMJD
pathology is mechanistically different from other reported inflammatory-induced TMJD models.
Based on my results, I propose that this model that involves pain signaling in response to
prolonged jaw opening in sensitized animals involves dysfunction of descending inhibitory
signaling and likely involves changes in the expression of cytokines and miRNAs.
KEYWORDS: temporomandibular joint disorder, trigeminal nerve, peripheral sensitization,
central sensitization, risk factors, inflammatory mediators
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INTRODUCTION

Temporomandibular Joint Disorder
Temporomandibular joint disorders (TMD) are common orofacial pain conditions that
can affect the temporomandibular joint (TMJ) or jaw joint and muscles of mastication.46 TMD is
the most prevalent type of orofacial pain and occurs in approximately 10% of the population
over age of 18.44, 67 There is a higher prevalence of TMD associated with the female gender with
increased prevalence in ages between 20 and 40, which corresponds to the time of childbearing
and career development.47, 67 The common TMD symptoms experienced by millions of American
adults include jaw pain/tenderness after or during mastication, jaw clicking, limited jaw
movement, tinnitus, and an increased number of headaches or migraine. 5

Risk Factors Associated with TMD
TMD is often seen as a comorbid condition with other types of chronic pain including
headaches and migraine, and neck and shoulder pain as well as psychological complaints such as
depression and anxiety.74 Results from the Orofacial Pain Prospective Evaluation and Risk
Assessment (OPPERA) Study provide evidence that prolonged jaw opening, neck muscle
tenderness, and female gender are commonly reported risk factors associated with the
development of chronic TMD.26 While genetic factors have been proposed to play a role in the
etiology of chronic pain conditions, only a few genes with low correlative values have been
associated with development of chronic TMD.68 One interpretation of these results is that TMD
is a complex polygenetic disease that involves not only genes involved in pain signaling but
likely genes that regulate the structure and function of key anatomical elements involved in
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mastication including the jaw joint and associated muscles as well as biopsychosocial behaviors.
While it has been shown that there is a low genetic predisposition present in TMD patients, it is
now thought that progression to chronic TMD is dependent to a large degree on epigenetic
changes that occur in response to one’s lifestyle and environment.22, 70 Some of the most
common causes of TMD is direct trauma to the head during sporting activities or motor vehicle
accidents and repeated near maximal jaw opening as occurs during yawning or singing.54, 67
However, a routine visit to the dentist or orthodontist in which a patient is forced to hold open
their jaw to near maximum for a prolonged duration should be considered a risk factor of
development of TMD. Prolonged jaw opening is common during procedures involving molar
extractions, root canals, and orthodontics. Given that on average females are not able to open
their mouth as wide as males and their masticatory ligaments and tendons are not as thick, there
is an increased risk of injury to the TMJ and associated structures in women. Interestingly, neck
muscle tenderness, a commonly reported condition in women, is considered a risk factor for the
development of chronic TMD since these muscles can affect the functioning of the masticatory
muscles.41, 75, 76 Neck muscle tension and tenderness that may exhibit multiple taut bands can
occur from a multitude of factors including whiplash, improper sleep position, sports injury,
overuse, improper positioning of the neck throughout the day or while sleeping, or unmanaged
stress. Pain and stiffness in shoulder and neck muscles, especially the upper trapezius, is often
cited as a co-morbid condition with TMD patients.
Trigeminal Nerve
Similar to other orofacial pain conditions such as migraine and chronic rhinosinusitis,
TMD involves sensitization and activation of the trigeminal nerve.11 The trigeminal nerve is the
fifth cranial nerve and serves to provide sensory innervation of structures throughout the head
2

and face and provides a pathway for pain transmission from peripheral tissues to the spinal
cord.63-66 The nerve is made up of three branches of which the first two branches the ophthalmic
(V1) and maxillary (V2) only are comprised of sensory afferent neurons that respond to thermal,
mechanical, and chemical stimuli. While sensitization and activation of V1 and V2 branches are
implicated in headache disorders, trigeminal neuralgia, and rhinosinusitis, the underlying
pathology associated with TMD primarily involves activation of the third branch, which is
referred to as the mandibular (V3) that possesses both sensory and motor neurons.61 The pain and
inflammation associated with TMD involves activation of primary V3 trigeminal ganglion
nerves that function to relay nociceptive signals from peripheral tissues such as the TMJ and
associated muscles of mastication (masseter) to the upper cervical spinal cord.1, 6, 13 The
nociceptive signal is transferred to second-order neurons in the medullary dorsal horn and then
via the ascending pain pathway is transmitted to the thalamus and on to higher brain structures
including the cortex for processing and coordinating a protective response to minimize further
tissue damage and initiate repair mechanisms.57, 61

Trigeminal System
The trigeminal system consists of the trigeminal ganglion, which is part of the peripheral
nervous system, and the trigeminocervical complex located in the central nervous system.4 There
are two main cell types that comprise the trigeminal system including neuronal cells that are
responsible for conduction of sensory information from the peripheral tissues to the spinal cord
and the associated glial cells that function to regulate the excitability state of the neurons.20 The
sensory fibers of the primary trigeminal nerves transmit mechanical, thermal, and chemical
information to the cell bodies located in the trigeminal ganglion. The pseudounipolar

3

morphology of the neurons within the ganglion can be differentiated into 2 types including large
light and small dark neurons. While the large light neurons are myelinated, fast transducing A
fibers that provide rapid reflexive response to harmful stimuli, the small dark neurons consist of
C fibers that are unmyelinated and thus have slower transduction but are responsible for longterm sensations and mediating prolonged inflammatory responses. Another functional aspect of
the ganglion is the supporting glial cells such as the Schwann cells that are associated with A
fibers and are responsible for the production of the myelin sheath that promotes faster conduction
within the peripheral nervous system. Another prominent glial cell in the ganglion is the satellite
glial cell, which surrounds the cell body of both A and C neurons, and as such form a functional
unit.21, 23 Satellite glial cells help to maintain homeostasis by controlling the level of ions and
neurotransmitters in the extracellular environment around the neuronal cell body by their
selective uptake and thus regulating the excitability state of both types of neurons.18, 28 Increased
communication between neuronal cell bodies and satellite glial cells via gap junctions and
paracrine signaling is associated with more chronic pain states as characteristic of most orofacial
disorders involving trigeminal nerve activation including TMD. The central nervous system
component of the trigeminal system consists of the second order neurons and the two main types
of glial cells, which include astrocytes and microglia that are responsible for modulating the
excitability level of spinal neurons.16, 50, 81 Similar to signaling in the trigeminal ganglion,
activation of astrocytes and microglia that facilitate neuron-glia communication is implicated in
the underlying pathology of chronic pain conditions by promoting and maintaining a heightened
state of sensitivity referred to as central sensitization.14, 37, 56, 80
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TMJD Pathology
Following an injury to the jaw joint, inflammatory signals are released that activate
primary afferent nerves of the trigeminal system, which can lead to the development of a
sensitized state within the peripheral tissue. During the sensitized state, neuronal cells can
produce an increased pain response (hyperalgesia) to a normal stimulus but will result in a
nociceptive response to sub-threshold, non-painful stimuli (allodynia) such as brushing one’s
teeth or chewing. These pathophysiological phenomena are mediated via cellular changes that
lower the amount of stimuli required to activate the nociceptive neurons. Sensitization involves
changes in the excitability of neurons by lowering the activation threshold to mechanical,
thermal, or chemical stimuli through molecular changes promoted by persistent nociceptive
input. This established sensitized state, which is maintained by release of pro-inflammatory
cytokines and chemokines from activated glial cells can lead to a persistent (primed) state of
hypersensitivity or hyperexcitability of trigeminal neurons.34, 42
During states of hypersensitivity, there is a reduced electric threshold of activation
required to open ion channels, delayed opening of inhibitory channels, or prolonged the opening
of excitatory channels. Prolonged peripheral sensitization can lead to central sensitization that
has the potential to become a chronic pathological condition long after the initiating event.
Constant input from the sensitized primary afferents leads to nociceptive neuronal
hyperexcitability within the medullary horn of the trigeminal nucleus caudalis.56 A prolonged
state of central sensitization is associated with pathological conditions characteristic of TMD.
Unfortunately, in some susceptible individuals, peripheral sensitization promotes and sustains
central sensitization that drives sensitization of higher-order neurons within the thalamus and
development of a chronic pain state that is no longer physiological but rather pathophysiological
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in nature. Thus, while acute inflammation and sensitization of the trigeminal system are
necessary to restore homeostasis following injury to the TMJ or associated masticatory
structures, prolonged sensitization can lead to changes in pain processing pathways that are no
longer associated with healing. During these chronic pain conditions, there is a heightened
nocifensive response in the absence of peripheral inflammation.
In response to peripheral activation of trigeminal nerves the neuropeptide calcitonin
gene-related peptide (CGRP) and other inflammatory mediators facilitate excitation of secondorder neurons and glial cells involved in central sensitization and persistent pain.12, 62 Elevated
CGRP levels in the spinal cord are known to promote the development of central sensitization
due to changes in ion channels, receptors, and inflammatory genes in second-order neurons and
glial cells.38 CGRP is involved in the initiation and maintenance of central sensitization by
activation of CGRP receptors present on secondary neurons and glial cells within the spinal cord
that couple to activation of protein kinase A (PKA). Following activation of CGRP receptors,
there is an increase in the secondary messenger cAMP, which then causes activation of the
intracellular signaling protein PKA. Persistent elevated active PKA levels leads to a sensitized
state of second-order neurons as well as activation of astrocytes and microglia that establish a
sustained primed state in which normally non-stimulating levels of neurotransmitters can now
cause activation.71
The central dogma of acute pain signaling is that peripheral sensitization promotes
cellular changes that lead to central sensitization of second-order nociceptive neurons involved in
pain transmission to the thalamus.4, 17, 61 However, in most chronic migraine and TMD patients,
the current thought is that central sensitization is maintained without any evidence of peripheral
tissue damage or trauma. While peripheral sensitization results from interactions of nociceptors
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with inflammatory substances released when a tissue is inflamed or damaged61, central
sensitization can be maintained in the absence of trigeminal nociceptor activation. In support of
this notion, findings from our studies have provided evidence of bidirectional signaling within
the trigeminal system.12 In this model, CGRP was injected intracisternally (upper spinal cord) to
mimic higher CGRP levels reported in cerebral spinal fluid of chronic migraine patients.
Somewhat surprisingly, elevated CGRP levels resulted in cellular changes associated with
central sensitization but also mediated increased neuron-glia communication with the ganglion
associated with the development and maintenance of peripheral sensitization of nociceptive
neurons. The evidence of bidirectional signaling within the trigeminal system may explain how
trigeminal peripheral nociceptive neurons become sensitized during chronic orofacial pain
conditions many days/weeks after resolution of inflammation. Thus, peripheral nociceptor
sensitization can occur even in the absence of any physical trauma or signs of inflammation.
As previously stated, there are several inflammatory molecules involved in the process of
initiating and maintaining neuronal sensitization. CGRP, which is expressed in both peripheral
and central neurons, is a known prominent inflammatory mediator that functions as a potent
vasodilator and potentiates protein extravasation, stimulates the release of cytokines from
satellite glial cells, performs autocrine signaling to stimulate synthesis of itself in the trigeminal
ganglion neurons, and reduces the threshold for depolarization of nociceptive neurons and glia.3
Chronic elevation of CGRP peripherally would lead to persistent pain and destruction of the TMJ
capsule, which is common in TMD. Within the spinal cord, central sensitization involves
increased interactions between neurons and spinal glia cells, specifically astrocytes and
microglia. Astrocytes are the most abundant cells within the brain and regulate the neuronal
environment by maintaining the blood-brain barrier and modulating ion, fluid, and
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neurotransmitter concentrations. Astrocytes can promote and sustain sensitization of central
neurons through the release of cytokines, chemokines, and other pro-inflammatory mediators
while microglia perform functions similar to peripheral macrophages within the brain and spinal
cord.49 When activated these specialized immune-like cells release inflammatory cytokines and
chemokines that can promote and sustain a persistent sensitized or primed state of neurons
characteristic of chronic pain conditions. These pro-inflammatory molecules often cause
activation of the nuclear transcription factor NF-κB, which binds to the promoter of cytokines
and chemokines to enhance their expression and hence, sustain elevated levels.43 Astrocytes and
microglia work together to control the excitability state of secondary nociceptive neurons by
maintaining a balance within the extracellular environment around the neurons. Towards this
end, these cells are known to express transport proteins for the uptake of potassium ions and
glutamate, which are molecules that promote activation of neuronal cells involved in pain
transmission.82 In addition, elevated levels of glial fibrillary associated protein (GFAP) and
ionized calcium binding adaptor molecule 1 (Iba1) are associated with activated astrocytes and
microglia.7, 55

Hypothesis and Goals of Research
Animal models of acute and chronic orofacial pain have been developed that mimic
human clinical pain conditions to study the cellular and molecular mechanisms involved in
mediating inflammation and pain signaling involving the trigeminal system. Many of these
models rely on the injection of inflammatory agents into the joint capsule or masticatory
muscles.8, 9, 23, 24, 40 Thus, these models are mimicking a traumatic peripheral event that elicits an
inflammatory reaction to promote tissue injury and minimize jaw activity. Interestingly, almost

8

all animal studies involving TMD pathology have been performed only in male animals, yet,
TMD is more prevalent in females. More recently in our laboratory, we developed a chronic
model of TMD pathology based on risk factors known to promote chronic TMD in humans,
which included neck muscle tension/inflammation, prolonged jaw opening, and female gender
(Figure 1). The model involves neck muscle inflammation prior to prolonged jaw opening. The
neck muscle inflammation promotes a sensitized state of trigeminal nociceptors such that
prolonged jaw opening results in a sustained increase in trigeminal nociception to mechanical
stimulation of the masseter muscle (Figure 2). The goal of my thesis project was to investigate
the changes in key signaling proteins in neuronal and glial cells involved in initiating and
maintaining the prolonged state of sensitization observed in this novel model of chronic TMD
pathology. Based on previous studies in our laboratory, I hypothesized that there would be an
increase in the pro-inflammatory proteins within the upper spinal cord to promote central
sensitization, and hence lower the activation threshold required for peripheral activation.

To test my hypothesis, I propose the following goals that involve utilizing
immunohistochemistry to investigate changes in protein expression in spinal cord tissues in a
novel model of chronic TMJD:
1. Determine changes in the levels of CGRP since it is implicated in the establishment of
central sensitization.
2. Study expression of PKA, the downstream intracellular pathway activated by CGRP in
mediating central sensitization in neurons and glial cells.
3. Determine if astrocytes and microglia are activated in this chronic model.
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4. Determine changes in the levels of the transcription factor NF-ΚB since increased
expression of this protein is associated with stimulated release of cytokines and
chemokines.
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Figure 1 Schematic Representation of a Chronic TMJD Model. See text for more details. Neck
muscle inflammation leads to sensitization among the ascending pain signaling pathway causing
the brain to detect the painful sensation. A second risk factor (prolonged jaw opening) is
introduced leading to more sensitized inflammation which activates the second order neurons
and glia cells causing pain signaling along the primary afferent neurons which leads to greater
ascending pain modulation and increased sensitization.
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Figure 2 Neck Muscle Pathology and Prolonged Jaw Opening Mediated Sustained Sensitized
Masseter Nociceptive State. The average number of head withdrawals in response to mechical
stimultion over the masseter muscle. See text for more details. (A) Male nociceptive state. (B)
Female nociceptive state.
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METHODS
Animals and Reagents
Animal protocols were approved by the Institutional Animal Care and Use Committee at
Missouri State University (IACUC ID: 17.001.0) and conducted in compliance with all
guidelines established by the National Institutes of Health Animal Welfare Act. Adult female
Sprague-Dawley rats (250-300g) were purchased from Charles River Laboratories Inc.
(Wilmington, MA) or purchased from Missouri State University (internal breeding colonies).
Animals were housed in clean, plastic cages (VWR, West Chester, PA) in an animal holding
room maintained at ambient temperature (22-24 C) with access to food and water ad libitum. The
holding room was on a 12-hour light/dark cycle starting at 7 A.M. These animals were allowed
to acclimate in this environment at least one week before use. Complete Freund’s adjuvant
(CFA, Sigma Aldrich, St. Louis, MO) was prepared as a 1:1 emulsion in 0.9% saline solution
(Fisher-Scientific, Pittsburgh, PA) immediately prior to use.

Model of Chronic TMJD
CFA was administered bilaterally into the upper trapezius muscles of young adult
Sprague-Dawley female rats to induce low-grade neck muscle inflammation (Figure 3). Prior to
the injection of CFA, animals were anesthetized with 5% isoflurane (Webster Veterinary,
Devens, MA) using oxygen as the carrier gas and a Vetequip isoflurane mixing apparatus
connected to the animal chamber. Upon completion of anesthetization, the rats were placed
ventral surface down and a nose cone apparatus was used to deliver a constant flow of 3%
isoflurane. A total of 100 µl CFA was delivered via five 10 µl intramuscular injections in both
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the right and left upper trapezius muscles using a 26 ½ gauge needle (Becton Dickinson,
Franklin Lakes, NJ) and a 50 µl Hamilton syringe (Hamilton Company, Reno, NV).
Following the CFA injections, eight days later the animals were subjected to prolonged
jaw opening as described previously30, 31 (Figure 4) to induce injury to the TMJ and associated
muscles, ligaments, and tendons anesthetized animals (5% isoflurance vs 3%). Under anesthesia
via inhalation of 5% isoflurane, animals were placed dorsal side down and attached to a nose
cone apparatus delivering a steady flow of 3% isoflurane. A commercially available mouth
retractor (Fine Scientific Tools, Foster City, CA), was positioned around the top and bottom
incisors. The retractor arms were separated until near maximal jaw opening was achieved and
then maintained for 20 minutes in this position. Using a CaliMax Vernier Caliper (Wiha Tools,
Montecillo, MN) the opening measurements were taken from the gingival line on the lingual
surface of the upper incisors to the gingival line on the lingual surface of the lower incisor. On
average, the maximum opening capacity without subluxation of the joint was approximately 20
mm for adult female Sprague-Dawley rats. Upon placement of the retractor, the animals were
returned to the animal chamber and were maintained in an anesthetized state with 3% isoflurane
for the duration of the jaw opening procedure. The breathing patterns and body temperatures
were monitored throughout the application, and the procedure was aborted if either physiological
parameter varied significantly from normal levels. Following mechanical stressing, the retractor
was released, removed, and the animal was allowed to recover in its cage prior to further
experimentation.

Immunohistochemistry
The methods utilized for immunohistochemistry were similar to prior studies from our
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lab.12, 40 The brain stem and upper spinal cord (6 mm posterior to the obex) were removed at 2
hours, 1 day, 14 days, and 28 days post prolonged jaw opening (Figure 5). The tissues were
immediately placed in 4% paraformaldehyde to preserve them for immunohistochemistry.
To investigate cellular changes in protein expression in neuronal and glial cells,
immunohistochemical staining of tissues was performed. The tissues were incubated in 4%
paraformaldehyde at 4°C overnight then were transferred into 15% sucrose for 1 hour at 4°C or
until they sank to the bottom of the centrifuge tube. Following the 15% sucrose incubation
tissues were moved to 30% sucrose and incubated at 4°C overnight. The tissues were removed
from the sucrose and stored at -20°C until sectioning. Prior to sectioning, tissues were embedded
in Optimal Cutting Temperature compound (OCT; Sakura Finetek, Torrance, CA). Transverse
sections 14 µm thick were taken between 4 and 5 mm caudal to the obex (about 75 sections from
top of tissue) using a cryostat (Richard Allan Scientific Co, San Diego, CA) set to -24°C. Tissue
sections were placed on Superfrost Plus microscope slides (Fisher Scientific, Pittsburg, PA) with
the caudal side facing down and stored at -20°C.
The slides containing sectioned tissues from naïve and each experimental condition were
rehydrated by incubation in 1X Phosphate Buffered Saline (PBS; 10 mM phosphate, 138 mM
NaCl, 27 mM KCl) for 5 minutes then blocked and permeabilized in a solution of 0.1% Triton
X-100 in 5% donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA) for 20
minutes at room temperature. During this incubation, primary antibodies of interest were
prepared according to the manufacturer’s recommended dilutions (Table 1) in 5% donkey serum.
Following the donkey + triton incubation, slides were thoroughly rinsed with PBS, and the
primary antibodies were incubated with tissues for either 3 hours at room temperature or
overnight at 4°C in a humidified chamber. After the primary antibody incubation, the slides were
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rinsed with PBS and 1% Tween 20. The tissues were then incubated with Alexa Fluorconjugated secondary antibodies prepared in PBS at a 1:200 dilution for 1 hour at room
temperature to visualize immunoreactive proteins. Vectashield medium (H-1200) containing 4’,
6- diamidino-2-phenylindole was used to mount the tissue sections and visualize cell nuclei
using fluorescent microscopy.
A Zeiss Axiocam mRm camera (Carl Zeiss, Thornwood, NY) mounted on a Zeiss Imager
Z1 fluorescent microscope equipped with an ApoTome was used to collect 100X images of the
medullary horn of the spinal cord tissue (Figure 6). Once the images were acquired, they were
analyzed using Image J software as previously described.12, 40 Fluorescent intensity was
measured in ten rectangular regions of approximately equal area in laminas I-III in the medullary
horn. Five random acellular regions outside of the region of interest were measured and the
average of these values was subtracted from the medullary horn values to account for
background signal. SPSS Statistics 21 software (IBM, North Castle, NY) was used to determine
outliers. It was determined using a parametric independent sample T-test that most of the data
was normally distributed, so a Shapiro-Wilk test was used followed by a Leavean’s test to
determine equal or unequal variances. For the data that was not normally distributed a
nonparametric test was used to determine statistically significance followed by a Mann-Whitney
U post hoc test. All statistical tests was conducted utilizing SPSS Statistics.
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Table 1 Summary of Antibodies and Conditions Used for Immunohistochemistry
Protein

Dilution
1:1000

Incubation
time
3 Hours

Incubation
Temperature
20-22°C

CGRP
GFAP

1:5000

3 Hours

20-22°C

Abcam, Inc.

Ab53554

Iba-1

1:1000

3 Hours

20-22°C

Wako Chemicals
USA, Inc.

019 - 19741

NeuN

1:1000

3 Hours

20-22°C

EMD Millipore,
Corp.

MAB377

P-ERK

1:500

OVN

4°C

Bioworld
Technology, Inc.

BS5016

PKA

1:500

3 Hours

20-22°C

Abcam, Inc.

Ab76238

cFos

1:500

OVN

20-22°C

Abcam, Inc.

Ab190289

CNX43

1:500

OVN

20-22°C

Abcam, Inc.

Ab11370

NF-ΚB

1:500

OVN

20-22°C

AbCam, Inc.

Ab16502

RAMP1

1:500

OVN

20-22°C

Bioss

Alexa-Fluor 488

1:200

1 Hour

20-22°C

JacksonImmuno
Research, Inc.

125719

Alexa-Fluor 647

1:200

1 Hour

20-22°C

JacksonImmuno
Research, Inc.

122180

DAPI

N/A

N/A

N/A

Vector
Laboratories

H-1200
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Company
Sigma-Aldrich,
Inc.

Catalog
number
C 8189

Bs-1567R

A)

B)

Figure 3 Induction of Prolonged Neck Muscle Inflammation. (A) This figure depicts the ten
different injection sites of CFA in the Trapezius muscle. (B) Image of the setup for
anesthetizing the animals.
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Figure 4 Mechanically-Induced Chronic TMJD Model. (A) Picture of lower jaw being
retracted to near maximum jaw opening. (B) Animals resting in chamber after retraction
distance was set. (C) Close-up image illustrating the position of retractor during procedure.
(D) Picture of isoflurane control condition.
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Figure 5 Experimental Timeline for Immunohistochemistry Studies.
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B

A

Figure 6 Identification of the Neuronal and Glial Cell Nuclei in the Rat Upper Spinal Cord. (A)
Entire upper spinal cord section from an untreated animal stained with DAPI to identify all
nuclei at 40X magnification. (B) Magnification (100X) of neuron containing the medullary horn
stained with DAPI. (C) Trigeminal nerve pathway showing sensory innervation pattern in the
head and face and projection through ganglion to upper spinal cord region known as spinal
trigeminal nucleus (http://www.orofacialpain.org.uk/education/trigeminal-nerve/). Arrow
indicates region of spinal cord shown in panels A and B.
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RESULTS
CGRP
Temporal changes in the expression of the pro-inflammatory neuropeptide CGRP in
neuronal cells located in the spinal trigeminal nucleus were investigated using
immunohistochemistry. In spinal cord tissues from naïve animals, CGRP staining was detected
predominantly in the outer lamina of the medullary dorsal horn at the 2 hour and 14 day time
points (Figures 7 and 8). The relative intensity of CGRP staining was not elevated over naïve
levels 2 hours or 14 days post jaw opening in sensitized animals (M+J; where M refers to neck
muscle injections and J refers to prolonged jaw opening). A summary of the fold-change ± SEM
of the relative intensity of CGRP immunostaining compared to naïve levels, whose mean was set
equal to one, is shown in Table 2 for all conditions. At 2 hours post prolonged jaw opening,
there were no significant changes in the localization pattern or intensity of staining in the M+J
animals when compared to naïve levels (fold 1.06, p = 0.202). The same was true of day 14
animals with no significant changes detected in the staining intensity or pattern for CGRP in the
M+J animals (fold 0.98, p = 0.748). Similarly, no differences were observed in CGRP levels in
M+J animals (fold 0.89, p = 0.447) and naïve animals at day 28. However, a small yet
significant increase in the intensity of CGRP immunostaining in M+J animals was found one day
post jaw opening when compared to naïve levels (fold 1.30, p = 0.007).

PKA
Levels of PKA in the medullary dorsal horn were evaluated to determine if increased
intracellular signaling downstream of CGRP receptor activation could be mediating sensitization
of trigeminal nociceptive neurons. In naïve animals, low levels of PKA immunostaining were
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detected within the medullary horn of the upper spinal cord in a pattern similar to that of CGRP
(Figure 9 and 10). In contrast to the CGRP results, no significant differences in PKA staining
pattern or intensity was observed between the M+J treated animals and naïve animals at any time
point. A summary of the average fold-change ± SEM of the relative intensity of PKA
immunostaining in M+J animals compared to naïve levels (mean set equal to one) is shown in
Table 3 for all conditions. At 2 hours post prolonged jaw opening, there were no significant
changes in the intensity in the M+J animals (fold 1.02, p = 0.844). The same was true of day 14
animals with no significant changes in the intensity in the M+J animals (fold 1.20, p = 0.086).
Similarly, no significant changes were observed in the relative staining intensity between the
M+J animals (fold 0.88, p = 0.401) and the naïve animals for day 1 or day 28 (fold 1.10, p =
0.237) post prolonged jaw opening.

NF-κB
Levels of transcription factor, NF-κB, were evaluated to determine if cytokine activation
could be involved in promoting the sensitized state of trigeminal nociceptive neurons, which was
examined using immunohistochemistry. In the upper spinal cord of the naïve animals, low levels
of NF-κB immunostaining were detected within the medullary horn (Figure 11 and 12). The
sensitized animals, which were the M+J treated animals, showed no significant differences from
the naïve animals. A summary of the fold-change ± SEM of the relative intensity of NF-κB
immunostaining compared to the naïve levels is shown in Table 4 for all conditions. At 2 hours
post prolonged jaw opening, there were no significant changes in the intensity of the staining in
the M+J animals when compared to the naïve animals (fold 0.81, p = 0.261). The same was true
of day 14 animals with no significant changes in the intensity or pattern for NF-κB in the treated

23

animals compared to the naïve animals (fold 0.98, p = 0.874). The same was true for M+J
animals (fold 0.86, p = 0.265) and naïve animals at day 28 post prolonged jaw opening. The
staining patterns of NF-κB for day 1 was not determined in this study.

GFAP
Examination of astrocyte activity in the upper spinal cord was completed through
analysis of GFAP immunostaining levels. In naïve animals, low levels of GFAP immunostaining
were detected within the medullary horn of the upper spinal cord (Figure 13 and 14). Summaries
of the average fold-change ± SEM of the relative intensity of GFAP immunostaining compared
to naïve levels (mean set equal to one) for all conditions are shown in Table 5. The M+J treated
animals showed no significant differences from the naïve animals. At 2 hours post-prolongedjaw opening, there were no significant changes in the intensity in the M+J animals (fold 0.78, p
= 0.343). The same was true of day 14 animals with no significant changes in the intensity in
the treated animals (fold 1.40, p = 0.073). There were no significant changes in the intensity
between the M+J animals (fold 0.98, p = 0.879) and the naïve animals for day 1 shown in Table
2 (staining not pictured). The same was true for M+J animals (fold 0.83, p = 0.303) and naïve
animals at day 28 post prolonged jaw opening.

Iba1
Activation of microglia within the upper spinal cord was assessed through
immunostaining of the microglial marker Iba1. In naïve animals, low levels of PKA
immunostaining were detected within the medullary horn of the upper spinal cord (Figure 15 and
16). Summaries of the average fold-change ± SEM of the relative intensity of Iba1
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immunostaining compared to naïve levels (mean set equal to one) for all conditions are shown in
Table 6. The M+J treated animals showed no significant differences from the naïve animals. At
2 hours post-prolonged-jaw opening, there were no significant changes in the intensity in the
M+J animals (fold 0.95, p = 0.717). The same was true of day 14 animals with no significant
changes in the intensity in the treated animals (fold 1.01, p = 0.462). There were no significant
changes in the intensity between the M+J animals (fold 1.40, p = 0.418) and the naïve animals
for day 1 shown in Table 2 (staining not pictured). The same was true for M+J animals (fold
0.75, p = 0.448) and naïve animals at day 28 post prolonged jaw opening.

25

Table 2 Summary of Fold Changes in CGRP Expression in the Medullary Horn of the Upper
Spinal Cord. All data are reported as the average fold change when compared to naïve levels,
which was made equal to 1 ± the standard error of the mean.
Protein

Time point

Naïve

M+J

CGRP

2hr

1.00 ± 0.02

1.06 ± 0.05

CGRP

Day 1

1.00 ± 0.05

1.30 ± 0.04 *

CGRP

Day 14

1.00 ± 0.03

0.98 ± 0.05

CGRP

Day 28

1.00 ± 0.04

0.89 ± 0.07

* = significantly different from the naïve
Significant is defined by p < 0.05
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Figure 7 No Significant Changes in CGRP Levels in the Upper Spinal Cord 2 hours after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of CGRP in naïve (top) and M+J
(bottom) (M+J; where M refers to neck muscle injections and J refers to prolonged jaw opening)
animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged imaged
of CGRP and DAPI staining is shown in the middle panels.
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Figure 8 No Significant Changes in CGRP Levels in the Upper Spinal Cord 14 days after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of CGRP in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of CGRP and DAPI staining is shown in the middle panels.
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Table 3 Summary of Fold Changes in PKA Expression in the Medullary Horn of the Upper
Spinal Cord. All data are reported as the average fold change when compared to naïve levels,
which was made equal to 1 ± the standard error of the mean.
Protein

Time point

Naïve

M+J

PKA

2hr

1.00 ± 0.04

1.02 ± 0.09

PKA

Day 1

1.00 ± 0.04

0.88 ± 0.16

PKA

Day 14

1.00 ± 0.09

1.20 ± 0.10

PKA

Day 28

1.00 ± 0.09

1.10 ± 0.03

Significant is defined by p < 0.05
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Figure 9 No Significant Changes in PKA Levels in the Upper Spinal Cord 2 hours after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of PKA in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of PKA and DAPI staining is shown in the middle panels.
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Figure 10 No Significant Changes in PKA Levels in the Upper Spinal Cord 14 days after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of PKA in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of PKA and DAPI staining is shown in the middle panels.
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Table 4 Summary of Fold Changes in NF-ΚB Expression in the Medullary Horn of the Upper
Spinal Cord. All data are reported as the average fold change when compared to naïve levels,
which was made equal to 1 ± the standard error of the mean.
Protein

Time point

Naïve

M+J

NF-ΚB

2hr

1.00 ± 0.12

0.81 ± 0.12

NF-ΚB

Day 1

ND

ND

NF-ΚB

Day 14

1.00 ± 0.09

0.98 ± 0.08

NF-ΚB

Day 28

1.00 ± 0.06

0.86 ± 0.11

Significant is defined by p < 0.05
ND = not determined
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Figure 11 No Significant Changes in NF-ΚB Levels in the Upper Spinal Cord 2 hours after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of NF-ΚB in naïve (top) and M+J
(bottom) animals. Sections were co-stained for neuronal nuclear expression of NeuN (right
panels) and merged imaged of NF-ΚB and NeuN staining is shown in the middle panels.
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Figure 12 No Significant Changes in NF-ΚB Levels in the Upper Spinal Cord 14 days after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of NF-ΚB in naïve (top) and M+J
(bottom) animals. Sections were co-stained for neuronal nuclear expression of NeuN (right
panels) and merged imaged of NF-ΚB and NeuN staining is shown in the middle panels.

34

Table 5 Summary of Fold Changes in GFAP Expression in the Medullary Horn of the Upper
Spinal Cord. All data are reported as the average fold change when compared to naïve levels,
which was made equal to 1 ± the standard error of the mean.
Protein

Time point

Naïve

M+J

GFAP

2hr

1.00 ± 0.17

0.78 ± 0.16

GFAP

Day 1

1.00 ± 0.18

0.98 ± 0.05

GFAP

Day 14

1.00 ± 0.09

1.40 ± 0.17

GFAP

Day 28

1.00 ± 0.16

0.83 ± 0.09

Significant is defined by p < 0.05
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Figure 13 No Significant Changes in GFAP Levels in the Upper Spinal Cord 2 hours after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of GFAP in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of GFAP and DAPI staining is shown in the middle panels.
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Figure 14 No Significant Changes in GFAP Levels in the Upper Spinal Cord 14 days after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of GFAP in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of GFAP and DAPI staining is shown in the middle panels.
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Table 6 Summary of Fold Changes in Iba1 Expression in the Medullary Horn of the Upper
Spinal Cord. All data are reported as the average fold change when compared to naïve levels,
which was made equal to 1 ± the standard error of the mean.
Protein

Time point

Naïve

M+J

Iba1

2hr

1.00 ± 0.17

0.95 ± 0.16

Iba1

Day 1

1.00 ± 0.20

1.40 ± 0.33

Iba1

Day 14

1.00 ± 0.37

1.01 ± 0.47

Iba1

Day 28

1.00 ± 0.33

0.75 ± 0.06

Significant is defined by p < 0.05
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Figure 15 No Significant Changes in Iba1 Levels in the Upper Spinal Cord 2 hours after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of Iba1 in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of Iba1 and DAPI staining is shown in the middle panels.
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Figure 16 No Significant Changes in Iba1 Levels in the Upper Spinal Cord 14 days after
Undergoing Prolonged Jaw Opening after CFA Capsule Injection. Images (100X) from the
representative region of medullary horn stained for expression of Iba1 in naïve (top) and M+J
(bottom) animals. Sections were co-stained with the nuclear dye DAPI (right panels) and merged
imaged of Iba1 and DAPI staining is shown in the middle panels.
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DISCUSSION
The goal of my thesis research was to investigate the cellular mechanisms associated with
sustained mechanical sensitivity in the masseter muscle in a novel model of TMJD pathology.
To mediate persistent pain signaling of trigeminal neurons, adult female rats that had ongoing
neck muscle inflammation were subjected to near maximal jaw opening. I hypothesized that the
underlying pathology would involve the development of central sensitization and a subsequent
lowering of the activation threshold of trigeminal neurons by increasing expression of proinflammatory proteins and neuron-glia interactions. However, a somewhat surprising finding of
my study was the lack of evidence to support my hypothesis, which however supports the notion
that our chronic TMJD model is not mechanistically similar to other established inflammationinduced TMJD models. Previous studies from our laboratory utilized injection of the
inflammatory mediator, complete Freund’s adjuvant, into both TMJ capsules to cause prolonged
joint inflammation and enhanced trigeminal nociception for up to 14 days in non-sensitized
animals.8, 9, 23, 24, 40 The CFA-induced TMJD model is likely relevant to human situations when
there is direct injury to the TMJ that would occur from a blow to the face during a sporting event
or a car accident. In response to tissue injury of the joint and disc, neurogenic inflammation
would result in the release of potent vasodilators and pro-inflammatory molecules such as CGRP
and nitric oxide and cause release of cytokines and chemokines from the synoviocytes and
recruitment of immune cells to facilitate tissue repair.10, 35, 36, 59, 69, 73 In the model of TMJD used
in my study, neck muscle inflammation is initiated one week prior to prolonged jaw opening to
simulate known reported risk factors for the development of chronic TMJD in humans.53, 67 Our
laboratory developed this chronic model to investigate the cellular and molecular changes that
lead to a prolonged state of trigeminal nociceptor sensitization. Based on my results,
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development of chronic TMJD in sensitized animals exposed to prolonged jaw opening, which
can occur while yawning, singing, or having a routine dental procedure, does not involve
upregulation of proteins associated with maintenance of central sensitization or activation of
astrocytes or microglia. Hence, this is a unique TMJD model that promotes trigeminal
sensitization via a different mechanism that does not follow the typical inflammatory peripheral
to central sensitization neuron-glia signaling pathway reported in acute TMJD models.61 Thus,
my findings may help to explain why patients with severe neck stiffness and evidence of taut
bends in the trapezius muscles do not respond as well to commonly used anti-inflammatory
medications such as nonsteroidal anti-inflammatory drugs or NSAIDs.27
A key feature of our chronic TMJD model is trapezius neck muscle inflammation, which
is a common complaint of orofacial pain patients prior to and during major pain episodes.
Anatomically, there is convergence of sensory stimuli from the primary trigeminal neurons and
neck muscle neurons at the level of the upper spinal cord such that both sets of these neurons can
cause activation of the ascending nociceptive second order neurons.2, 51, 60, 78 Interestingly, the
signaling pathways involved in muscle pain in general and neck muscle pain in particular have
not been well studied. Although not a focus of my study, my results are suggestive that neck
muscle inflammation promotes a sensitized state of trigeminal nociceptors that does not involve
cellular and molecular changes implicated in central sensitization and facilitation of ascending
pain signaling from second order trigeminal neurons to the thalamus and higher brain structures.
Furthermore, my results provide evidence that astrocytes and microglial cells are not activated in
response to neck muscle inflammation or following prolonged jaw opening in our chronic TMJD
model. This finding is quite surprising given the large number of studies that implicate
activation of astrocytes and microglia in the initiation and maintenance of a persistent or primed
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state of nociceptive neurons.16, 48, 57, 77, 79, 80 Alternatively, neck muscle inflammation likely
mediates downregulation or dysregulation of the inhibitory descending pain modulation
pathway, which would result in an enhanced or hyperexcitable state of the trigeminal system
(Figure 17). With respect to pain modulation and establishing threshold levels, nociceptive
neuron sensitivity could be enhanced because of changes in the ascending signaling pathway via
increased ion channel and receptor activity and increased neuron-glia interactions, which could
be thought of as a gain-of-function.11, 19, 32, 52, 56 However, a loss of function would also be
expected to play a major role in modulating the activation threshold of trigeminal neurons to
peripheral stimuli, which can occur if there is a reduction or loss of signaling in the descending
inhibitory pathway. Hence, dysregulation of the descending pathway would generate a
hypervigalent nervous system that would be more responsive to inflammatory stimuli. I can only
speculate that neck muscle inflammation mediates increased sensitization as a protective
mechanism since most of the major senses are located in the head and face. Therefore, if one
does not have full range of motion of one’s head because of neck inflammation, the nervous
system responds by increasing the sensitivity of incoming peripheral stimuli to facilitate a
hypervigalent state characteristic of TMD and migraine patients. The descending inhibitory
pathway plays an important physiological role by quieting the nervous system and controlling
the amount of sensory input that reaches the higher brain centers. Thus, minimizing the
allostatic load on the system. This inhibitory pathway is activated turning states of deep sleep,
meditation involving deep breathing, and in response to our natural endorphins and even
morphine to inhibit peripheral sensory stimuli from reaching higher brain areas.11 This pathway
is also responsible in part to the “runner’s high” that allows elite athletes to block pain signaling
and is elicited during extreme cases of stress when the fight and flight response is initiated.
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Recent studies in our laboratory have provided evidence that non-invasive vagus nerve
stimulation (nVNS) activates this pathway and is able to inhibit trigeminal nociceptor sensitivity
in a model of chronic migraine.29 The mechanism is likely to involve activation of the
periaquaductal grey and rostral ventral medulla pathway and release of serotonin to cause
activation of inhibitory interneurons within the spinal cord. Upon activation of serotonin
receptors, these interneuronal cells release the inhibitory neurotransmitter GABA (gammaaminobutyric acid), which upon binding to GABA receptors on the second order neurons,
mediates an increase in intacellular chloride levels to cause hypopolarization and effectively
prevent activation of ascending nociceptive neurons. Whether the inclusion of grape seed
extract, which we have shown inhibits the development of a sensitized trigeminal system and
pain signaling in response to prolonged jaw opening in our chronic TMJD model, functions
similarly to nVNS to enhance facilitation of the descending inhibitory pathway will be a focus of
future studies.
In summary, I did not observe an increase in the expression of proteins implicated in the
development of central sensitization in neurons or glial cells in the medullary dorsal horn at any
time point following prolonged jaw opening in sensitized animals. Specifically, CGRP and
PKA were not consistently elevated even though these proteins are reported to promote the
development of central sensitization in other pain models.62, 71 Similarly, I investigated changes
in the transcription factor NF-ΚB since it has been reported to stimulate the synthesis of proinflammatory cytokines including TNF-α, IL-1β, and IL-6 and contribute to central
sensitization.15, 25, 33, 39, 45, 58, 72 However, I did not see an increase in the level of nuclear
localization of NF-ΚB in neurons or glial cells. Additionally, I did not detect changes in the
levels of GFAP or Iba1, which are biomarkers of activated astrocytes and microglia,
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respectively. Although not reported in my thesis, I also looked at the expression of several other
pro-inflammatory proteins including the transcription factor c-Fos, the gap junction protein
connexin 43, and the activated forms of the mitogen-activated protein kinases P-ERK (phosphoERK) and P-p38 (phospho-p38), but did not observe increased levels in our chronic TMJD
model.
In conclusion, results from my study did not support my hypothesis that the prolonged
sensitization observed in our chronic TMJD models would be mediated by pro-inflammatory
proteins implicated in central sensitization and glial cell activation. Rather, my findings support
the notion that the underlying pathology in our TMJD model likely involves dysregulation of the
descending inhibitory pathway. In future studies it will be of interest to investigate in our model
if there are corresponding changes in cytokine mRNA and protein levels, which can be studied
using microarray analysis, qPCR, and specific ELISA. Other studies will focus on understanding
the cellular and molecular mechanisms by which dietary inclusion of a grape seed extract
enriched in polyphenols and nVNS function to inhibit trigeminal mechanical sensitivity in our
chronic TMJD model.
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Figure 17 Dysregulation of Descending Modulation Likely Mediating Trigeminal Sensitization
in Chronic TMJD Model. See text for detailed description.

46

REFERENCES

[1] Ballegaard V, Thede-Schmidt-Hansen P, Svensson P, Jensen R. Are headache and
temporomandibular disorders related? A blinded study. Cephalalgia : an
international journal of headache 2008;28(8):832-841.
[2] Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts
and synthesis. Current pain and headache reports 2003;7(5):371-376.
[3] Benemei S, Nicoletti P, Capone JG, Geppetti P. CGRP receptors in the control of pain and
inflammation. Curr Opin Pharmacol 2009;9(1):9-14.
[4] Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective
and implications to migraine pathophysiology. J Clin Neurol 2012;8(2):89-99.
[5] Bevilaqua-Grossi D, Lipton RB, Napchan U, Grosberg B, Ashina S, Bigal ME.
Temporomandibular disorders and cutaneous allodynia are associated in
individuals with migraine. Cephalalgia : an international journal of headache
2010;30(4):425-432.
[6] Bevilaqua Grossi D, Lipton RB, Bigal ME. Temporomandibular disorders and migraine
chronification. Curr Pain Headache Rep 2009;13(4):314-318.
[7] Brahmachari S, Fung YK, Pahan K. Induction of glial fibrillary acidic protein expression
in astrocytes by nitric oxide. J Neurosci 2006;26(18):4930-4939.
[8] Cady RJ, Denson JE, Durham PL. Inclusion of cocoa as a dietary supplement represses
expression of inflammatory proteins in spinal trigeminal nucleus in response to
chronic trigeminal nerve stimulation. Mol Nutr Food Res 2013;57(6):996-1006.

47

[9] Cady RJ, Denson JE, Sullivan LQ, Durham PL. Dual orexin receptor antagonist 12 inhibits
expression of proteins in neurons and glia implicated in peripheral and central
sensitization. Neuroscience 2014;269:79-92.
[10] Carleson J, Alstergren P, Appelgren A, Appelgren B, Kopp S, Theodorsson E, Lundeberg
T. A model for experimental induction of acute temporomandibular joint
inflammation in rats: effects of substance P(SP) on neuropeptide-like
immunoreactivity. Life Sci 1996;59(15):1193-1201.
[11] Chichorro JG, Porreca F, Sessle B. Mechanisms of craniofacial pain. Cephalalgia : an
international journal of headache 2017;37(7):613-626.
[12] Cornelison LE, Hawkins JL, Durham PL. Elevated levels of calcitonin gene-related
peptide in upper spinal cord promotes sensitization of primary trigeminal
nociceptive neurons. Neuroscience 2016;339:491-501.
[13] Dahan H, Shir Y, Velly A, Allison P. Specific and number of comorbidities are associated
with increased levels of temporomandibular pain intensity and duration. J Headache
Pain 2015;16:528.
[14] Davies AJ, Kim YH, Oh SB. Painful Neuron-Microglia Interactions in the Trigeminal
Sensory System. TOPAINJ 2010(3da):14-28.
[15] Dinarello CA. Proinflammatory cytokines. Chest 2000;118(2):503-508.
[16] Dodds KN, Beckett EA, Evans SF, Grace PM, Watkins LR, Hutchinson MR. Glial
contributions to visceral pain: implications for disease etiology and the female
predominance of persistent pain. Transl Psychiatry 2016;6(9):e888.
[17] Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications.
Headache 2006;46 Suppl 4:S182-191.
48

[18] Dublin P, Hanani M. Satellite glial cells in sensory ganglia: their possible contribution
to inflammatory pain. Brain, behavior, and immunity 2007;21(5):592-598.
[19] Dubner R, Ren K. Brainstem mechanisms of persistent pain following injury. J Orofac
Pain 2004;18(4):299-305.
[20] Durham PL. Diverse Physiological Roles of Calcitonin Gene-Related Peptide in
Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote
Peripheral and Central Sensitization. Curr Pain Headache Rep 2016;20(8):48.
[21] Durham PL, Garrett FG. Emerging importance of neuron-satellite glia interactions
within trigeminal ganglia in craniofacial pain. TOPAINJ 2010;3:3-13.
[22] Fillingim RB, Ohrbach R, Greenspan JD, Knott C, Diatchenko L, Dubner R, Bair E,
Baraian C, Mack N, Slade GD, Maixner W. Psychological factors associated with
development of TMD: the OPPERA prospective cohort study. J Pain 2013;14(12
Suppl):T75-90.
[23] Garrett FG, Durham PL. Differential expression of connexins in trigeminal ganglion
neurons and satellite glial cells in response to chronic or acute joint inflammation.
Neuron Glia Biol 2009:1-12.
[24] Garrett FG, Hawkins JL, Overmyer AE, Hayden JB, Durham PL. Validation of a novel ratholding device for studying heat- and mechanical-evoked trigeminal nocifensive
behavioral responses. J Orofac Pain 2012;26(4):337-344.
[25] Gosselin RD, Suter MR, Ji RR, Decosterd I. Glial cells and chronic pain. Neuroscientist
2010;16(5):519-531.
[26] Greenspan JD, Slade GD, Bair E, Dubner R, Fillingim RB, Ohrbach R, Knott C, Mulkey F,
Rothwell R, Maixner W. Pain sensitivity risk factors for chronic TMD: descriptive
49

data and empirically identified domains from the OPPERA case control study. J Pain
2011;12(11 Suppl):T61-74.
[27] Haggman-Henrikson B, Alstergren P, Davidson T, Hogestatt ED, Ostlund P, Tranaeus S,
Vitols S, List T. Pharmacological treatment of oro-facial pain - health technology
assessment including a systematic review with network meta-analysis. J Oral
Rehabil 2017;44(10):800-826.
[28] Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain
Res Rev 2005;48(3):457-476.
[29] Hawkins JL, Cornelison LE, Blankenship BA, Durham PL. Vagus nerve stimulation
inhibits trigeminal nociception in a rodent model of episodic migraine. Pain reports
2017;2(6):e628.
[30] Hawkins JL, Durham PL. Prolonged Jaw Opening Promotes Nociception and Enhanced
Cytokine Expression. Journal of oral & facial pain and headache 2016;30(1):34-41.
[31] Hawkins JL, Durham PL. Enriched Chicken Bone Broth as a Dietary Supplement
Reduces Nociception and Sensitization Associated with Prolonged Jaw Opening.
Journal of oral & facial pain and headache 2018.
[32] Heinricher MM. Pain Modulation and the Transition from Acute to Chronic Pain. Adv
Exp Med Biol 2016;904:105-115.
[33] Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: Expression and
recognition. Trends Neurosci 1995;18(2):83-88.
[34] Hucho T, Levine JD. Signaling pathways in sensitization: toward a nociceptor cell
biology. Neuron 2007;55(3):365-376.

50

[35] Hutchins B, Patel H, Spears R. Attenuation of pro-inflammatory neuropeptide levels
produced by a cyclooxygenase-2 inhibitor in an animal model of chronic
temporomandibular joint inflammation. J Orofac Pain 2002;16(4):312-316.
[36] Ichikawa H, Fukunaga T, Jin HW, Fujita M, Takano-Yamamoto T, Sugimoto T. VR1-,
VRL-1- and P2X3 receptor-immunoreactive innervation of the rat
temporomandibular joint. Brain research 2004;1008(1):131-136.
[37] Ikeda H, Kiritoshi T, Murase K. Contribution of microglia and astrocytes to the central
sensitization, inflammatory and neuropathic pain in the juvenile rat. Mol Pain
2012;8:43.
[38] Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in
peripheral and central pain mechanisms including migraine. Pain 2017;158(4):543559.
[39] Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization:
distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis
factor-alpha in regulating synaptic and neuronal activity in the superficial spinal
cord. J Neurosci 2008;28(20):5189-5194.
[40] Koop LK, Hawkins JL, Cornelison LE, Durham PL. Central Role of Protein Kinase A in
Promoting Trigeminal Nociception in an In Vivo Model of Temporomandibular
Disorders. Journal of oral & facial pain and headache 2017;31(3):264-274.
[41] Koutris M, Visscher CM, Lobbezoo F, Naeije M. Comorbidity negatively influences the
outcomes of diagnostic tests for musculoskeletal pain in the orofacial region. Pain
2013;154(6):927-932.

51

[42] Kress M. Nociceptor Sensitization by Proinflammatory Cytokines and Chemokines.
TOPAINJ 2010;3:97-101.
[43] Lee M. Neurotransmitters and microglial-mediated neuroinflammation. Curr Protein
Pept Sci 2013;14(1):21-32.
[44] LeResche L. Epidemiology of temporomandibular disorders: implications for the
investigation of etiologic factors. Critical reviews in oral biology and medicine : an
official publication of the American Association of Oral Biologists 1997;8(3):291305.
[45] Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation
2010;7:27.
[46] List T, Jensen RH. Temporomandibular disorders: Old ideas and new concepts.
Cephalalgia : an international journal of headache 2017;37(7):692-704.
[47] Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, Ahlberg J, Lobbezoo F. Research
diagnostic criteria for temporomandibular disorders: a systematic review of axis I
epidemiologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2011;112(4):453-462.
[48] McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain
mediators and modulators. Exp Neurol 2005;192(2):444-462.
[49] Miller RJ, Jung H, Bhangoo SK, White FA. Cytokine and chemokine regulation of
sensory neuron function. Handbook of experimental pharmacology 2009(194):417449.
[50] Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain.
Nature reviews Neuroscience 2009;10(1):23-36.
52

[51] Morch CD, Hu JW, Arendt-Nielsen L, Sessle BJ. Convergence of cutaneous,
musculoskeletal, dural and visceral afferents onto nociceptive neurons in the first
cervical dorsal horn. Eur J Neurosci 2007;26(1):142-154.
[52] Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal
dysfunction of a brainstem descending modulatory center in migraine patients. PloS
one 2008;3(11):e3799.
[53] Ohrbach R, Fillingim RB, Mulkey F, Gonzalez Y, Gordon S, Gremillion H, Lim P-F,
Ribeiro-Dasilva M, Greenspan JD, Knott C, Maixner W, Slade G. Clinical Findings and
Pain Symptoms as Potential Risk Factors for Chronic TMD: Descriptive Data and
Empirically Identified Domains from the OPPERA Case-Control Study. The journal of
pain : official journal of the American Pain Society 2011;12(11 Suppl):T27-T45.
[54] Ohrbach R, Fillingim RB, Mulkey F, Gonzalez Y, Gordon S, Gremillion H, Lim PF,
Ribeiro-Dasilva M, Greenspan JD, Knott C, Maixner W, Slade G. Clinical findings and
pain symptoms as potential risk factors for chronic TMD: descriptive data and
empirically identified domains from the OPPERA case-control study. J Pain
2011;12(11 Suppl):T27-45.
[55] Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein Iba1
binds to fimbrin and enhances its actin-bundling activity. Journal of neurochemistry
2004;88(4):844-856.
[56] Ren K, Dubner R. Central nervous system plasticity and persistent pain. J Orofac Pain
1999;13(3):155-163; discussion 164-171.
[57] Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr
Opin Anaesthesiol 2008;21(5):570-579.
53

[58] Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: Actions and
mechanisms of action. Trends Neurosci 1995;18(3):130-136.
[59] Sato J, Segami N, Kaneyama K, Yoshimura H, Fujimura K, Yoshitake Y. Relationship of
calcitonin gene-related peptide in synovial tissues and temporomandibular joint
pain in humans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98(5):533540.
[60] Sessle BJ. Neural mechanisms and pathways in craniofacial pain. Can J Neurol Sci
1999;26 Suppl 3:S7-11.
[61] Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain. Int Rev
Neurobiol 2011;97:179-206.
[62] Seybold VS. The role of peptides in central sensitization. Handbook of experimental
pharmacology 2009(194):451-491.
[63] Shankland WE. The trigeminal nerve. Part II: the ophthalmic division. Cranio
2001;19(1):8-12.
[64] Shankland WE, 2nd. The trigeminal nerve. Part I: An over-view. Cranio
2000;18(4):238-248.
[65] Shankland WE, 2nd. The trigeminal nerve. Part III: The maxillary division. Cranio
2001;19(2):78-83.
[66] Shankland WE, 2nd. The trigeminal nerve. Part IV: the mandibular division. Cranio
2001;19(3):153-161.
[67] Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE, Dubner R,
Diatchenko L, Meloto CB, Smith S, Maixner W. Painful Temporomandibular Disorder:
Decade of Discovery from OPPERA Studies. J Dent Res 2016;95(10):1084-1092.
54

[68] Smith SB, Maixner DW, Greenspan JD, Dubner R, Fillingim RB, Ohrbach R, Knott C,
Slade GD, Bair E, Gibson DG, Zaykin DV, Weir BS, Maixner W, Diatchenko L. Potential
genetic risk factors for chronic TMD: genetic associations from the OPPERA case
control study. J Pain 2011;12(11 Suppl):T92-101.
[69] Spears R, Dees LA, Sapozhnikov M, Bellinger LL, Hutchins B. Temporal changes in
inflammatory mediator concentrations in an adjuvant model of temporomandibular
joint inflammation. J Orofac Pain 2005;19(1):34-40.
[70] Su N, Lobbezoo F, van Wijk A, van der Heijden GJ, Visscher CM. Associations of pain
intensity and pain-related disability with psychological and socio-demographic
factors in patients with temporomandibular disorders: a cross-sectional study at a
specialised dental clinic. J Oral Rehabil 2017;44(3):187-196.
[71] Sun RQ, Tu YJ, Lawand NB, Yan JY, Lin Q, Willis WD. Calcitonin gene-related peptide
receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and
central sensitization. J Neurophysiol 2004;92(5):2859-2866.
[72] Uceyler N, Schafers M, Sommer C. Mode of action of cytokines on nociceptive neurons.
Exp Brain Res 2009;196(1):67-78.
[73] Uddman R, Grunditz T, Kato J, Sundler F. Distribution and origin of nerve fibers in the
rat temporomandibular joint capsule. Anat Embryol (Berl) 1998;197(4):273-282.
[74] Visscher CM, Lobbezoo F, de Boer W, van der Zaag J, Naeije M. Prevalence of cervical
spinal pain in craniomandibular pain patients. European journal of oral sciences
2001;109(2):76-80.

55

[75] Visscher CM, Schouten MJ, Ligthart L, van Houtem CM, de Jongh A, Boomsma DI.
Shared Genetics of Temporomandibular Disorder Pain and Neck Pain: Results of a
Twin Study. Journal of oral & facial pain and headache 2018;32(2):107-112.
[76] Visscher CM, van Wesemael-Suijkerbuijk EA, Lobbezoo F. Is the experience of pain in
patients with temporomandibular disorder associated with the presence of
comorbidity? European journal of oral sciences 2016;124(5):459-464.
[77] Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells
contribute to pathological pain states. Physiol Rev 2002;82(4):981-1011.
[78] Watson DH, Drummond PD. Head pain referral during examination of the neck in
migraine and tension-type headache. Headache 2012;52(8):1226-1235.
[79] Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain.
Neurochem Int 2004;45(2-3):389-395.
[80] Xie YF. Glial involvement in trigeminal central sensitization. Acta Pharmacol Sin
2008;29(6):641-645.
[81] Xie YF, Zhang S, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. Involvement of glia in
central sensitization in trigeminal subnucleus caudalis (medullary dorsal horn).
Brain, behavior, and immunity 2007;21(5):634-641.
[82] Xin WJ, Weng HR, Dougherty PM. Plasticity in expression of the glutamate transporters
GLT-1 and GLAST in spinal dorsal horn glial cells following partial sciatic nerve
ligation. Mol Pain 2009;5:15.

56

